BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19713051)

  • 1. Exploring the relationship between perceived inter-dose opioid withdrawal and patient characteristics in methadone maintenance treatment.
    Elkader AK; Brands B; Callaghan R; Sproule BA
    Drug Alcohol Depend; 2009 Dec; 105(3):209-14. PubMed ID: 19713051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients.
    Elkader AK; Brands B; Dunn E; Selby P; Sproule BA
    J Clin Psychopharmacol; 2009 Feb; 29(1):77-81. PubMed ID: 19142113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of symptom complaints in methadone maintenance patients.
    Dyer KR; White JM
    Addiction; 1997 Nov; 92(11):1445-55. PubMed ID: 9519488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depression in methadone maintenance treatment patients: rate and risk factors.
    Peles E; Schreiber S; Naumovsky Y; Adelson M
    J Affect Disord; 2007 Apr; 99(1-3):213-20. PubMed ID: 17055063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans.
    Donny EC; Walsh SL; Bigelow GE; Eissenberg T; Stitzer ML
    Psychopharmacology (Berl); 2002 May; 161(2):202-12. PubMed ID: 11981600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of levo-alpha-acetylmethdol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal: a pharmacokinetic and pharmacodynamic analysis.
    Newcombe DA; Bochner F; White JM; Somogyi AA
    Drug Alcohol Depend; 2004 Oct; 76(1):63-72. PubMed ID: 15380290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of the dose on the severity of opiate withdrawal symptoms during methadone detoxification.
    Glasper A; Gossop M; de Wet C; Reed L; Bearn J
    Pharmacology; 2008; 81(2):92-6. PubMed ID: 17952010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Craving despite extremely high methadone dosage.
    de Vos JW; Ufkes JG; van Brussel GH; van den Brink W
    Drug Alcohol Depend; 1996 Mar; 40(3):181-4. PubMed ID: 8861396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships.
    Dyer KR; Foster DJ; White JM; Somogyi AA; Menelaou A; Bochner F
    Clin Pharmacol Ther; 1999 Jun; 65(6):685-94. PubMed ID: 10391674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid addicts at admission vs. slow-release oral morphine, methadone, and sublingual buprenorphine maintenance treatment participants.
    Giacomuzzi S; Kemmler G; Ertl M; Riemer Y
    Subst Use Misuse; 2006; 41(2):223-44. PubMed ID: 16393744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression.
    Kastelic A; Dubajic G; Strbad E
    Addiction; 2008 Nov; 103(11):1837-46. PubMed ID: 19032534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of opioid craving over time as measured by visual analog scales.
    McMillan DE; Gilmore-Thomas K
    Drug Alcohol Depend; 1996 Mar; 40(3):235-9. PubMed ID: 8861402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive functioning during methadone and buprenorphine treatment: results of a randomized clinical trial.
    Soyka M; Lieb M; Kagerer S; Zingg C; Koller G; Lehnert P; Limmer C; Kuefner H; Hennig-Fast K
    J Clin Psychopharmacol; 2008 Dec; 28(6):699-703. PubMed ID: 19011441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pupillometric changes during gradual opiate detoxification correlate with changes in symptoms of opiate withdrawal as measured by the Weak Opiate Withdrawal Scale.
    Rosse RB; Johri S; Goel M; Rahman F; Jawor KA; Deutsch SI
    Clin Neuropharmacol; 1998; 21(5):312-5. PubMed ID: 9789712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methadone-nicotine interactions in methadone maintenance treatment patients.
    Elkader AK; Brands B; Selby P; Sproule BA
    J Clin Psychopharmacol; 2009 Jun; 29(3):231-8. PubMed ID: 19440076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methadone maintenance treatment: the need to distinguish between holding dose, dose adequacy, satisfaction with methadone as a medication, and satisfaction with treatment.
    Trujols J; SiƱol N; de los Cobos JP
    J Clin Psychopharmacol; 2010 Feb; 30(1):95-6; author reply 96. PubMed ID: 20075667
    [No Abstract]   [Full Text] [Related]  

  • 17. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers.
    Donny EC; Brasser SM; Bigelow GE; Stitzer ML; Walsh SL
    Addiction; 2005 Oct; 100(10):1496-509. PubMed ID: 16185211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetyl-L-carnitine in the management of pain during methadone withdrawal syndrome.
    Janiri L; Martinotti G; Tonioni F; Ghelardini C; Nicolai R; Galeotti N; Mosconi L; Calvani M; Bartolini A; Iannoni E
    Clin Neuropharmacol; 2009; 32(1):35-40. PubMed ID: 18978503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When "enough" is not enough: new perspectives on optimal methadone maintenance dose.
    Leavitt SB; Shinderman M; Maxwell S; Eap CB; Paris P
    Mt Sinai J Med; 2000; 67(5-6):404-11. PubMed ID: 11064491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans.
    Foltin RW; Fischman MW
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1153-64. PubMed ID: 8819498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.